What’s inside
View ResearchA retrospective cohort study published in Frontiers in Allergy (2026;7:1865860; PMID 42358593) of 2,897 patients treated with customized at-home sublingual immunotherapy for environmental allergies through Curex. Clinically meaningful symptom improvement was reported by 28% of patients at 12 months and 45% at 24 months; adherence exceeded 90%; adverse events were infrequent and mostly mild, with no anaphylaxis. The study is observational and was authored by Curex clinicians, so it describes real-world outcomes rather than proving efficacy against a control group.
Study design and population
Retrospective cohort of 2,897 patients prescribed customized sublingual immunotherapy drops and dosed at home, with telehealth follow-up.
Symptom improvement over time
Clinically meaningful improvement rose from 28% of patients at 12 months to 45% at 24 months of treatment.
Adherence
Adherence to daily at-home dosing exceeded 90%, higher than persistence reported in earlier real-world immunotherapy studies.
Safety
Adverse events were infrequent and mostly mild local reactions; no cases of anaphylaxis were reported.
Limitations
Observational, single-provider, Curex-authored, no control group; results describe real-world outcomes, not comparative efficacy.
Regulatory context
Customized multi-allergen sublingual drops are prescribed off-label in the US; only single-allergen sublingual tablets are FDA-approved.
.svg)
.jpg)
.webp)
